MILLON
Besançon, 25000, France
Location status: Recruiting
Location contact
Florent DEMONMEROT
CONTACT
NCT Number: NCT05824442
Echinococcosis is a severe parasitosis caused by the development of the tapeworm larva Echinococcus multilocularis, responsible for alveolar echinococcosis (AE) or Echinococcus granulosus, responsible for cystic echinococcosis (CE). The treatment is based on surgery (only possible in 30 to 40% of cases) and/or on a benzimidazole antiparasitic treatment, especially albendazole. Albendazole is only parasitostatic, it slows down the development of the parasite but does not kill it. It is often prescribed for life. Monitoring the effectiveness of the treatment is therefore necessary, requiring radiological and serological monitoring once or twice a year. Being a chronic disease whose treatment is not always curative, patients quality of life is impacted, with a high level of anxiety described in some patients.
The diagnosis, evoked on radiological arguments, is then confirmed by serological techniques, whose sensitivity for EA diagnosis is good (95%) in the absence of immunosuppression (now observed in 25% of EA patients). Sensitivity is lower for CE diagnosis (70% or even less than 50% in certain clinical forms).
Quantitative real-time PCR (QPCR) techniques on blood samples are now used in many infectious pathologies to quantify the circulating DNA load, and improve diagnosis and therapeutic monitoring. The presence of circulating parasitic DNA has been reported in both types of echinococcosis.
A new Echinococcus spp.multiplex QPCR technique (QPCR-Echino) allowing the detection of DNA from E. multilocularis and different species of the E. granulosus complex of European occurrence, in different types of biological samples, has recently been developed in the French National Reference Center for Echinococcosis laboratory.
The investigators wish to evaluate QPCR-Echino for the detection of DNA in tissues, as well as in blood, for the diagnosis of Echinococcosis. This technique could improve the sensitivity of biological diagnosis, especially in immunocompromised patients, who often experience significant diagnostic delays, and could also provide information on the virulence and viability of the strains involved.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Besançon, 25000, France
Location status: Recruiting
Florent DEMONMEROT
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Blood sampling specifically for qPCR Echino at inclusion and one year after
Time frame: 1 year
sensitivity of DNA detection by QPCR-Echino in tissues (operating specimens, biopsies, puncture fluids) and in blood (plasma)
Contact information is provided by the study sponsor or research team.
Jenny KNAPP, PhD
CONTACT
Laurence MILLON, PharmD, PhD
CONTACT
Centre Hospitalier Universitaire de Besancon
Other
Acronym: HIS-QPCR-ECH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07715435
Cestode Infections, Echinococcosis
Alessandria, Piemonte, Italy, Italy
View Trial DetailsNCT06006429
Dental Caries, Diagnosis
Reims, France
View Trial DetailsNCT07011394
Asthma, Asthma in Children
Montreal, Quebec, Canada
View Trial DetailsNCT06320236
Cardiovascular Diseases, D-dimer
Hamilton, Ontario, Canada
View Trial Details